Glioblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Twelve glioblastomas (40%) showed amplification of the EGFR gene, and overexpression of EGFR was evident in each of these tumors as indicated by the immunoperoxidase technique.
|
7815080 |
1995 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The other patient had a glioblastoma which contained amplified epidermal growth factor receptor (EGFR) genes, and amplified EGFR gene sequences were present in her CSF.
|
7912724 |
1994 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In astrocytomas, for example, losses of genetic material on chromosomes 10 and 17 and amplification of the epidermal growth factor receptor gene seem important in pathogenesis, with the loss of chromosome 10 and the amplification of epidermal growth factor receptor being strongly associated with glioblastoma multiforme.
|
8008171 |
1994 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The oncogene MET was amplified in a glioblastoma which showed no EGFR gene amplification.
|
8017863 |
1994 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Western blot analysis with anti-phosphotyrosine antibody indicates that the mutant receptor is constitutively phosphorylated in CHO cells, and the same analysis applied to lysates of glioblastoma biopsies reveals the altered receptor is readily detectable as a phosphotyrosine protein in tumors for which there is evidence of corresponding EGFR gene and transcript alterations.
|
8036013 |
1994 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we used retroviral transfer of such a mutant receptor (de 2-7 EGFR) into glioblastoma cells expressing normal endogenous receptors to test whether the mutant receptor was able to augment their growth and malignancy.
|
8052651 |
1994 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To characterize some of the genetic events underlying the development of glioblastoma multiforme, the authors analyzed 65 astrocytic tumors (seven pilocytic astrocytomas, eight astrocytomas, 16 anaplastic astrocytomas, and 34 glioblastomas multiforme) for loss of heterozygosity for chromosome 17p, loss of heterozygosity for chromosomes 10p and 10q, amplification of the epidermal growth factor receptor (EGFR) gene, and amplification of the oncogenes N-myc, c-myc, and N-ras using Southern blot analysis.
|
8057151 |
1994 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma.
|
8262681 |
1994 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, those glioblastomas with a loss of chromosome 17p occurred in patients significantly younger than those with glioblastomas characterized by EGFR gene amplification (p = 0.001).
|
8269081 |
1993 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For example, one mutant form, the type III deletion mutant of the EGFR, that has been identified in glioblastomas contains a novel peptide sequence in its extracellular domain which is detectable by anti-peptide antisera.
|
8391918 |
1993 |
Glioblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression of epidermal growth factor receptor in human glioblastoma multiforme.
|
8393321 |
1993 |
Glioblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The first three have been reported in a few per cent of malignant gliomas, and EGFR in around 40% of glioblastomas.
|
8448375 |
1993 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This finding contradicts the hypothesis that deletion of one entire chromosome 10 regularly precedes EGFR gene amplification in primary glioblastomas of patients aged over 50 years.
|
8568531 |
1995 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most commonly amplified genes in glioblastomas are EGFR (in approximately 40%), CDK4, and SAS (in approximately 15%).
|
8586464 |
1995 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Immunostaining of glioblastomas revealed binding in the case with the type III EGFR mutation, the five other specimens without the mutation being negative despite overexpression of EGFR in some cases.
|
8645581 |
1996 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A positive EGFR immunoreaction was detected in seven (16%) of 44 WHO Grade II astrocytomas, five (26%) of 19 WHO Grade III astrocytomas, and 32 (52%) of 62 WHO Grade IV glioblastomas.
|
8814167 |
1996 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Only one out of 49 glioblastomas showed EGFR overexpression and a p53 mutation.
|
8864278 |
1996 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.
|
8895767 |
1996 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme.
|
8905754 |
1996 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFRvIII is a mutant epidermal growth factor receptor found in glioblastoma, and in carcinoma of the breast, ovary, and lung.
|
8962138 |
1996 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
None of the primary low-grade and none of the recurrent high-grade tumors (7 anaplastic astrocytomas, 10 anaplastic oligodendrogliomas, 4 anaplastic oligoastrocytomas, and 5 glioblastomas) showed evidence of EGFR gene amplification.
|
8965097 |
1996 |
Glioblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have selectively targeted the EGFr in human glioblastoma cells with kinase-deficient mutants of the erbB family derived from the ectodomain of the Neu oncogene that are able to form heterodimers with EGFr and inhibit EGFr-dependent phenotypes.
|
9096379 |
1997 |
Glioblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results are at variance with similar studies in adult patients in which primary and secondary glioblastomas are characterized by EGFR overexpression and p53 mutations, respectively, suggesting that the evolution of pediatric glioblastomas follows different genetic pathways.
|
9210874 |
1997 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.
|
9217972 |
1997 |
Glioblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
|
9393744 |
1997 |